IRLAB obtains strengthened patent protection for Phase II candidate pirepemat

September 2, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company has been granted a new patent on the manufacturing process for the drug candidate pirepemat by the US Patent Office. Pirepemat is one of IRLAB’s clinical drug candidates and under development in Phase IIb for the treatment of impaired balance and falls in Parkinson’s disease.

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company has been granted a new patent on the manufacturing process for the drug candidate pirepemat by the US Patent Office. Pirepemat is one of IRLAB’s clinical drug candidates and under development in Phase IIb for the treatment of impaired balance and falls in Parkinson’s disease.

The granted patent, US 11,078,158 B2, specifically covers a chemical process for manufacturing pirepemat in its pure form. This is critical to secure the future production of pirepemat in industrial scale once a drug based on pirepemat is approved and available on the market.

“We are pleased to successfully make progress in strengthening our clinical project portfolio’s patent protection. The US is one of the largest and key markets, which makes this issued patent a valuable addition to the commercial potential of pirepemat,” said Nicholas Waters, CEO at IRLAB.